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INTRODUCTION
Various clinical studies have demonstrated that the majority of tumor entities contain hypoxic regions by virtue of limitations in oxygen diffusion and perfusion. 1) These microenvironments provide an opportunity for tumor progression and contribute to the development of malignant phenotype, which is related to a poor prognosis and local tumor relapse. 2, 3) Meanwhile, the cells in the hypoxic regions are more resistant to radiotherapy for reduction in life span of DNA-damaging free radicals and augmentation post-irradiation molecular restoration. 4) Hypoxia has been identified as a potent stimulus for several transcription factors. 5) Therefore, new strategies for hypoxia-specific gene therapy and targeting these transcription factors are certainly promising in anti-tumor efficacy. 4) SirT1 is a mammalian class-III protein deacetylase of the sirtuin family that can deacetylate non-histone proteins in the nucleus (SirT1, 6, 7), cytoplasm (SirT2) or mitochondria (SirT3, 4, 5). 6) Because of the dependency on nicotinamide adenine dinucleotide (NAD + ) for enzymatic reaction, the activity of SirT1 is regulated by the (NAD + )/NADH ratio and is therefore directly associated with cell metabolic status. 7) Accordingly, by reducing NADH consumption in mitochondria and increasing NADH production from glycolysis, hypoxia reduces the (NAD + )/NADH ratio and hence lowers the levels of SirT1 transcript. 8) Furthermore, SirT1 targets many transcriptional regulators including p53, FOXO, Rb, E2F1, HIC1, BCL6, 9) NF-κB, 10) and plays a pivotal role in transcriptional silencing, aging, chromosomal stability and DNA damage response. It was reported that the malignant cells or tissues from patients have a high level of SirT1, suggesting that oncogenic transformation may induce the expression of SirT1. 9) In addition, down regulation of SirT1 expression in vitro by antisense oligonucleotides or in vivo by small interference RNA has been shown to sensitize cancerous cells to radiation and enhance radiation-induced apoptosis. 11, 12) By deacetylating and inactivating apoptotic proteins, SirT1 may exert important functions in the DNA repair pathways and protect cancer cells from apoptosis induced by DNA damage. 13) However, the application of antisense oligonucleotides or sh-RNA is potentially limited by ineffective delivery into cancer cells.
Belonging to the transcription factors of Myc family, c-Myc plays an essential role in controlling numerous cell biological effects such as proliferation, angiogenesis, senescence, oncogenesis, metabolism, DNA damage response, and genetic stability. 14) The c-Myc amplification, customarily accompanied with an increased expression, is critical for hepatocarcinogenesis and therefore portends a poor prognosis. C-Myc is known to be a regulator for apoptosis. Deregulation of c-Myc can induce apoptosis under certain circumstances. Moreover, recent works show that c-Myc is required for DNA damage-induced apoptosis in the G2 phase of cell cycle. 15, 16) Obviously, c-Myc plays a key role in tumor radiotherapy.
There might have close relationship between Sirt1 and cMyc for solid tumor resistance to chemo-and/or radio-therapy. Despite the intense scrutiny of SirT1 for one decade, relatively little information has been focused on the molecular mechanisms underling radiation response linking SirT1 and c-Myc signaling pathway in hypoxic cells. Given that SirT1 and c-Myc play important roles in cell survival, which may serve as a new promising target for cancer therapy, the present study investigated whether activation or inhibition of SirT1 by pharmacological agents could produce parallel changes in radiation-induced DNA damage under hypoxia condition. Our results revealed that inhibition of SirT1 in hypoxic hepatoma HepG2 cells enhanced the anticancer effect of radiation by stabilizing c-Myc protein, indicating that inhibition of Sirt1 expression and/or its activity may be a potential approach for tumor radiotherapy.
METHODS AND MATERIALS

Cell culture
HepG2 cells were obtained from the Shanghai Cell Bank of China and maintained in DMEM medium (HyClone, Beijing, China) containing glucose (4.5 g/l) and supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), glutamate (4 mM) and 10% fetal bovine serum (Gibco Invitrogen, Grand Island, NY, USA) in a fully humidified incubator with 5% CO2 at 37°C.
Establishment of hypoxic culture condition
For hypoxia treatment, HepG2 cells were transferred to a hypoxic incubator (Huaxi Electronic Science and Technology, Hunan, China) with an auto-purge airlock. Environmental hypoxia condition was achieved in this airtight humidified incubator containing 1% O2, 5% CO2 and 94% N2 at 37°C. The cells were maintained in the hypoxia incubator for at least 12 h, and the efficiency of hypoxia treatment was evaluated by the oxygen enhancement ratio 17) of irradiated cells as that shown below.
Chemical treatments
Nicotinamide (Sigma, St. Louis, MO, USA), a putative inhibitor of SirT1 deacetylase activity, 18) and 10058-F4 [(Z, E)-5-(4-Ethyl-benzylidine)-2-thioxo-thiazolidin-4-one] (Calbiochem, San Diego, CA, USA) were applied as the inhibitor of SirT1 and c-Myc protein, respectively. Resveratrol (Trans-3,4',-5-tri-hydro-xystilebene) (Sigma) was widely used as a potent activator of SirT1 protein. 19) MG132 (Sigma) was applied to inhibit proteasome. The drug's cytotoxicity was measured with the Cell Counting Assay Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan) and the IC 50 values of resveratrol, nicotinamide and 10058-F4 were 505.5 μM, 63.03 mM and 346.9 μM, respectively. Here, the drugs with sub-lethal concentrations were used, and 0.1% DMSO was applied as the control when the drug was stocked in DMSO.
For the drug treatment, exponentially growing HepG2 cells were pretreated for 0.5 h with 150 μM resveratrol, 15 mM nicotinamide and 80 μM 10058-F4, respectively, followed by continual incubation in a regular normoxic incubator or a hypoxic incubator for 12 h before irradiation. Some cells were treated with nicotinamide together with 10058-F4 for 12 h before irradiation. In ubiquitin-mediated protein degradation experiments, HepG2 cells were treated with resveratrol plus 1 μM MG132 for 12 h before irradiation.
Cell irradiation
HepG2 cells were seeded on a 35-mm Petri dish (1 × 10 5 cells/dish) and allowed to grow for one day. After treatment with chemicals for 12 h under hypoxia condition, cell dishes sealed in a box filled with N2 gas were irradiated at room temperature with γ-rays at a dose rate of 0.79 Gy/min using a 137 Cs irradiator (Gammacell-40, MDS Nordion Inc., Toronto, Ontario, Canada). Immediately after irradiation, the cells were washed triply with hypoxic PBS in an airtight hypoxic bench (Model YQX-1, Shanghai Yuejin Mdeical Instruments Ltd., Shanghai, China) then harvested for further analysis or these cells were maintained with fresh hypoxic medium and transferred to the hypoxia incubator for further 2 hours' incubation until MN assay. Control samples were treated in the same way, except of irradiation.
Clonogenic survival assay
After 12 h hypoxia treatment, both normoxic and hypoxic HepG2 cells were irradiated with 0, 2, 4, 6, 8 or 10 Gy of γ-rays. Then adherent cells were trypsinized and resuspended immediately, plated into 60-mm dishes at appropriate dilutions and incubated for 2 weeks at 37°C in a humidified atmosphere containing 5% CO2 and 95% air. The colonies were stained with crystal violet, and the colonies containing at least 50 cells were counted for cell survival assay. Survival fraction (SF) was calculated as the ratio of the plating efficiency (PE) of irradiated cells to the PE of control cells without irradiation. Data are presented as the mean ± SEM of colony counts in three to four plates, and the error bars for all survival data represent the 95% confidence intervals for normalized data points as calculated by Fieller's theorem. 20) The cell survival curves were fitted with the multi-target 
Micronuclei (MN) scoring
MN were measured using the cytokinesis-block technique. The cells were treated with 1.5 μg/ml cytochalasin-B for 28 h and then fixed with methanol/acetic acid (9:1 v/v) for 20 min. Air-dried cells were stained with 0.01% acridine orange (Sigma) then observed under a fluorescence microscope (Olympus, Tokyo, Japan). MN were scored in at least 500 binucleated cells and the MN yield, Y MN , was calculated as the ratio of the number of MN to the scored number of binucleated cells.
Western blotting assay
SirT1 and c-Myc antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Tubulin antibody was purchased from Beyotime Biotechnology (Jiangsu, China). HRP-conjugated secondary antibodies were purchased from Proteintech Group Inc. (Chicago, IL, USA). At indicated time interval after each treatment, cells (1.5 × 10 6 ) were harvested and the cell lysate was prepared as described by He et al.. 21) An equal amount of total protein was subjected to 10% SDS-PAGE and transferred to PVDF membrane (Millipore, Bedford, MA, USA). Membranes were probed with primary antibodies as indicated. Tubulin was used for loading control.
SirT1 deacetylase activity assay
For the measurement of cellular SirT1 deacetylase activity, nuclear proteins were extracted and SirT1 deacetylase activity was colorimetrically measured by the SirT1 Deacetylase Activity Assay Kit (Genmed Scientifics Inc., Arlington, MA, USA) following to the manufacturer's instructions. 22) The kit provided a SirT1 substrate with an acetylated peptide fragment derived from p53, known to be deacetylated by SirT1, and pre-labeled by p-Nitroaniline. After deacetylation by SirT1, aminopeptidase cleaved the deacetylated substrate and generated a highly chemiluminescent molecule group of p-Nitroaniline. The optical densities (OD) at a wavelength of 405 nm were recorded with a spectrophotometer (Diareader ELX800G, Dialab GmbH, Vienna, Austria).
Statistical analysis
Statistical analysis was compiled on the means of the data obtained from three independent experiments with three replicates in each case. All data are expressed as means ± S.E. The significance of differences in data of different groups are appropriately determined by the unpaired Student's t-test or the one-way analysis of variance (ANOVA) at P < 0.05 using the SPSS 13.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS
Radiation sensitivity under normoxia and hypoxia conditions
HepG2 cells were maintained at normoxia or hypoxia conditions for 12 h then irradiated with graded doses of γ-rays, and the cell survival fractions are illustrated in Fig. 1 . According to these survival data, the OER value was calculated to be 2.74, indicating that the hypoxia incubator flushed with the mixed gases of N 2 and CO 2 was good enough to generate a hypoxia condition where the cells became resistant to irradiation.
SirT1 enhanced radioresistance on hypoxic HepG2 cells
To investigate the role of SirT1 in radiation damage under normoxic and hypoxic conditions, the normoxic and hypoxic HepG2 cells were pretreated for 12 h with resveratrol or nicotinamide, respectively, and then exposed to 3 Gy of γ-rays. Our pilot experiment showed that 3 Gy irradiation could generate appropriate response for both normoxic and hypoxic HepG2 cells and was optimal for the following further mechanism studies. As shown in Fig. 2, MN were induced in the irradiated cells, and the addition of resveratrol, the potent activator of SirT1, markedly suppressed radiation-induced MN formation in hypoxic cells, whereas resveratrol had no effect on the irradiated normoxic cells. But when the cells were treated with nicotinamide, a putative negative regulator of SirT1 deacetylase activity, 18 ) the yield of radiation-induced MN was enhanced much more under hypoxia than normoxic condition (56.62% vs 30.76%). To prove the critical role of SirT1 on radiosensitivity, our further investigation with plasmid mediated SirT1 over-expression and knock-down in the irradiated HepG2 cells under normoxic and hypoxic conditions also showed that the radiation-induced MN were dramatically suppressed when SirT1 was over-expressed, and in contrast, the MN was markedly enhanced when SirT1 was knocked-down. Under both situations of SirT1 over-expression and knock-down, the function of SirT1 in hypoxic cells was stronger than that in normoxic cells (data will be published elsewhere). These results indicate that SirT1 may contribute to the radioresistance induced by hypoxia stress on HepG2 cells.
We further tested the possible role of c-Myc in the above SirT1-related radioresistant effect by treating the normoxic and hypoxic HepG2 cells with 10058-F4, a c-Myc specific inhibitor. Figure 2 illustrates that the radiosensitivity of HepG2 cells was extensively decreased by 10058-F4. Moreover, this c-Myc inhibitor also eliminated the MN formation in the irradiated cells that were treated with the combination of nicotinamide and 10058-F4, which strongly suggest that the role of SirT1 in radioresistance may be, at least in part, modulated via the c-Myc pathway.
Modulation of SirT1 expression and deacetylase activity
After confirming the existence of SirT1 in hypoxic HepG2 cells, we than measured the expression of SirT1 in the drug treated cells. It was found that the resveratrol stimulation had a significant effect on SirT1 protein expression, whereas nicotinamide did not significantly alter SirT1 protein level (Fig. 3A) . Further investigation found that γ-ray irradiation did not significantly alter the deacetylase activity of SirT1 during hypoxia. However, as expected, resveratrol not only enhanced the expression of SirT1 protein but also increased the deacetylase activity of SirT1 remarkably (Fig.  3B) . Oppositely, when the hypoxic cells were treated with nicotinamide, a physiological inhibitor of SirT1 deacetylase activity, the deacetylase activity of SirT1 decreased dramatically, suggesting that the radioprotection role of SirT1 was mediated by its deacetylase activity in hypoxic HepG2 cells.
SirT1 negatively regulated c-Myc accumulation during hypoxia
The observation in Fig. 2 prompted us to detect the effect of resveratrol and nicotinamide on the expression of the cMyc. Western blotting experiments revealed that c-Myc protein level was markedly regulated by resveratrol in hypoxic HepG2 cells (Fig. 4) . Stimulation of SirT1 by resveratrol led to decrease in c-Myc protein expression in the hypoxic conditions. Error bars indicate the standard error of the mean (SEM) from at least three independent experiments with three replicates in each case. ***, P < 0.001 compared to non-irradiated control; the arrow and *** P < 0.001 between the indicated groups. Fig. 5 illustrates clearly that the resveratrol treatment could aggravate the degradation of hypoxia-induced c-Myc, whereas nicotinamide delayed this process. These observations were consistent with the phenomenon that the cells expressing higher c-Myc level were more susceptible to irradiation.
23)
SirT1 induced degradation of c-Myc via ubiquitin-proteasome
It has been known that the expression of c-Myc in normoxic cells has a short half-life of approximately 30 min because of the ubiquitin protein degradation by proteasome. To further determine whether the loss of c-Myc in resveratrol-treated hypoxic HepG2 cells was associated with the protein degradation, HepG2 cells were pretreated with the proteasome inhibitor MG132, widely used for the inhibition of ubiquitin-mediated proteolysis, in the presence of resveratrol. As shown in Fig. 5, MG132 prevented the resveratrolinduced loss of c-Myc in the hypoxic cells, suggesting that the resveratrol could reduce the expression of c-Myc protein by activating a proteasome dependent degradation process in the hypoxic HepG2 cells.
DISCUSSION
In this study, we compared the radiation effects of SirT1 activator (resveratrol) and SirT1 inhibitor (nicotinamide) on normoxic and hypoxic HepG2 cells, and found that hypoxic cells were much more susceptible to resveratrol and nicotinamide (Fig. 2) . The present study showed that the pretreatment of hypoxic HepG2 cells with resveratrol increased markedly the expression and activity of SirT1 and alleviated the effects of γ-ray irradiation on MN formation strikingly. This is consistent with the observations that resveratrol acted as a potent radiation-protection agent both in vitro and in vivo. [24] [25] [26] Previous studies indicated that resveratrol not only acts as a natural activator of SirT1 deacetylase activity, 19) but also increases SirT1 protein expression. 27) Thus, it can be expected that resveratrol exerts radioresistance in hypoxic HepG2 cells via SirT1 activation. Our results also showed that, even under the pretreatment with resveratrol, the MN induction in irradiated HepG2 cells was still not fully eliminated to the background level, which suggests that other SirT1-independent mechanism may be involved in the radioresistance effect of resveratrol and some unknown Error bars indicate the standard error of the mean (SEM) from at least three independent experiments. **, P < 0.01 and ***, P < 0.001 between the indicated groups. Rev, resveratrol; Nico, nicotinamide; MG, MG132; IR, irradiation. molecular factors could affect SirT1 activation in response to resveratrol under certain circumstances.
In contrast, nicotinamide, a strong noncompetitive inhibitor of SirT1 both in vitro and in vivo, 28) promoted radiationinduced DNA damage significantly. This compound is ubiquitous in most mammalian cells and acts as a physiological inhibitor of SirT1 by sequestering a key intermediate. 29) As expected, treatment of HepG2 cells with nicotinamide significantly decreased the deacetylase activity of SirT1 and enhanced radiation-induced MN formation. It has been reported that down-regulation of SirT1 expression in vitro by antisense oligonucleotides can induce apoptosis and enhance radiation sensitization in lung cancer cells.
11) Chang et al. also found that knockdown of SirT1 expression enhanced radiation-induced apoptosis in CD133-positive glioma cells. 12) In addition, Sirt1-null embryos exhibited an impaired DNA damage response, such as chromosome abnormalities, aneuploidy, cell cycle abnormalities, as well as a deficiency in DNA repair. 30) In response to DNA damage, SirT1 could dissociate from repetitive DNA and relocalize to DNA breaks to promote DNA repair. 17) In response to DNA damage, SirT1 could promote cell survival by deacetylating DNA repair proteins such as KU70 31) or by deacetylating various substrate proteins involved in DNA damage response, including p53, 32, 33) NF-κ B, 10) and cMyc. 34) Taken together, these evidences suggest that SirT1 may serve as an important factor in repairing DNA damage and maintaining genomic integrity.
Recent studies reported that activation of SirT1 by resveratrol and other small molecules was strongly dependent on structural feature of the peptide substrate, and the SirT1 activation effect of resveratrol to the present is still controversial. 35, 36) However, our additional investigation with plasmid mediated SirT1 over-expression and knock-down in the irradiated HepG2 cells under normoxic and hypoxic conditions showed that the radiation-induced MN were negatively regulated by SirT1. These results definitely support the current issue that SirT1 contributes to the radioresistance induced by hypoxia stress on HepG2 cells.
In order to evaluate whether cell susceptibility to radiation was in line with c-Myc, we measured the expression of cMyc and found that the radioresistance of hypoxic HepG2 cells had a parallel relationship with the decrease of the amount of c-Myc protein, in agreement with other's findings that the down-regulation of c-Myc caused cells to be resistance towards radiation and chemotherapeutic agents. 23) Accumulating evidence reveals that activation of c-Myc elicits DNA damage response in both ROS-dependent and ROS-independent manners, which could directly or indirectly facilitate genome instability and chromosomal abnormalities. 16) Our observations accord with above previous findings, showing that nicotinamide suppressed c-Myc protein degradation via inhibition of SirT1 deacetylase activity thus augmented radiation-induced DNA damage under hypoxia condition. Conversely, the sensitization of nicotinamide to radiation was almost eliminated when the cells were treated together with 10058-F4, a specific inhibitor of c-Myc, which further demonstrates that SirT1 exerts radioresistance due to the inhibition of c-Myc. 16) However, it was reported that the decreased level of c-Myc protein could increase cell sensitivity to radiation and cisplatin treatment of human melanoma cells, 37, 38) suggesting that the positive effect of c-Myc seems to be cell type-specific. On the other hand, when the irradiated HepG2 cells were pre-treated with 10058-F4 or 10058-F4 plus nicotinamide, the yield of MN was still not completely eliminated to the background level, suggesting that more radiation-responsible factors other then c-Myc might be certainly involved in the radiation-induced damage.
Given the regulation of the cellular response to DNA damage, we could conclude SirT1 as a sensor of radioresistance of hypoxic cells. However, the role of SirT1 is currently controversial because it can also act as a tumor suppressor by deacetylating HIF-1α so as to inhibit HIF-1α-mediated adaptation to hypoxia and offer a therapeutic targeting of tumors and their microenvironments. 39) Nevertheless, Dioum et al. reported that SirT1 selectively binds and stimulates the activity of HIF-2α but not HIF-1α. 40) Given that HIF-1α suppresses but HIF-2α promotes cell growth, SirT1 may activate HIF-2α to conduct cellular response in early phase of hypoxia, then, facilitate HIF-1α to take over hypoxic signaling.
39) The exact effect of SirT1 in cancer is intricate and its function may be cancer-specific and connects with cancerous cell status, and further investigations are required to determine the precise role of SirT1 in hypoxic signaling. Our results suggest that inhibition of SirT1 in combination with irradiation may be a promising strategy in blocking hypoxiainduced progression of tumor development and thus could advance the efficiency of radiation therapy in hepatoma.
